Literature DB >> 24965840

Functional characterization of NTRK1 mutations identified in melanoma.

Claudia Miranda1, Mara Mazzoni, Marialuisa Sensi, Marco A Pierotti, Angela Greco.   

Abstract

Cutaneous melanoma is the most aggressive form of skin cancer, with a complex and heterogeneous aetiology. Deregulation of the mitogen activated protein kinase cascade is common in melanoma, due to activating mutations in the BRAF and NRAS genes. Genetic studies and high-throughput screening technologies have recently identified several somatic mutations affecting different receptor tyrosine kinase (RTK) genes. For the majority of these, however, the contribution to the complexity of melanoma biology has not been assessed. Among these, two novel missense somatic mutations (M379I and R577G) have recently been identified in the gene encoding the neurotrophic RTK NTRK1. The NTRK1 melanoma-associated point mutations were introduced in a NTRK1 expression plasmid. Functional characterization of mutants was assessed after transient and stable transfection in HeLa and NIH3T3 cells, respectively. We showed that M379I and R577G NTRK1 receptors do not display the kinase as constitutively activated and are functionally indistinguishable from the wild-type NTRK1 receptor. Our results indicate that a causative role for M379I and R577G NTRK1 mutations in melanoma development is highly unlikely. This supports the issue that, in parallel to systematic large scale cancer genome screening, functional studies are required to distinguish between mutations that play a causative role in tumor development and others that may only be passenger changes.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24965840     DOI: 10.1002/gcc.22200

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

1.  Prostatic adenocarcinoma with novel NTRK3 gene fusion: a case report.

Authors:  Yunshin A Yeh; Shu Yang; Michael Constantinescu; Catherine Chaudoir; Anthony Tanner; Mishala Henry; Sheila Anderson; Juan-Sebastian Saldivar; Faye Serkin; Tajammul Fazili; Aubrey A Lurie; Xiuping Yu
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

Review 2.  TRK Inhibitors: Clinical Development of Larotrectinib.

Authors:  Munveer S Bhangoo; Darren Sigal
Journal:  Curr Oncol Rep       Date:  2019-02-04       Impact factor: 5.075

Review 3.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

Review 4.  NTRK fusion-positive cancers and TRK inhibitor therapy.

Authors:  Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

Review 5.  Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers.

Authors:  Tingting Jiang; Guan Wang; Yao Liu; Lu Feng; Meng Wang; Jie Liu; Yi Chen; Liang Ouyang
Journal:  Acta Pharm Sin B       Date:  2020-05-23       Impact factor: 11.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.